Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03995147 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
A Phase 2 study of Lymphoma and Diffuse Large B Cell Lymphoma, sponsored by University of Chicago.
- Active
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 1
- Study location
NCT03995147: Active Phase 2 study of Lymphoma and Diffuse Large B Cell Lymphoma, sponsored by University of Chicago.
NCT03995147 is a Phase 2 study of Lymphoma and Diffuse Large B Cell Lymphoma that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 51 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03995147, a Phase 2 study of Lymphoma and Diffuse Large B Cell Lymphoma, is active but no longer recruiting, sponsored by University of Chicago.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will research untreated non-germinal center diffuse large B cell lymphoma and what causes the disease and the way patients respond to pembrolizumab combined with R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) therapy.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG R-CHOP Protocol
Study Locations (1)
Illinois
- The University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2019-08-29 |
| Est. Completion | 2027-02-20 |
| Phase | Phase 2 |
What the registry record for NCT03995147 still lists
NCT03995147 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (89% lower).
The record links to 5 conditions, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03995147 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT03995147 about?
NCT03995147 is a clinical study titled "Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma". This study will research untreated non-germinal center diffuse large B cell lymphoma and what causes the disease and the way patients respond to pembrolizumab combined with R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) therapy.
What is the current status of trial NCT03995147?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2019-08-29. Estimated completion is 2027-02-20.
What conditions does trial NCT03995147 study?
This clinical trial studies the following conditions: Lymphoma, Diffuse Large B Cell Lymphoma, B-cell Lymphoma, Lymphoma, B-Cell, High Grade B-Cell Lymphoma.
What interventions are being tested in trial NCT03995147?
The interventions under investigation include: Pembrolizumab (DRUG), R-CHOP Protocol (DRUG).
Who is sponsoring clinical trial NCT03995147?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03995147 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03995147's enrollment target sits among peer trials
51 145th of 299 higher than 153 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI